ライフサイエンスコーパス: treatment for

1 were at high risk for fracture, romosozumab treatment for 12 months followed by alendronate resulted

2 GSK2330672 treatment for 14 days was safe with no serious adverse e

3 Participants were randomly assigned to treatment for 16 weeks of either a binocular iPad game p

4 Treatment for 16 weeks with once-daily subcutaneous inje

5 mmediately before treatment and 5 days after treatment for 16S rRNA gene sequencing.

6 Rosuvastatin treatment for 2 years resulted in significantly less pro

7 Hg) were randomized to placebo or metoprolol treatment for 22 weeks.

8 Overall, treatment for 30min showed significant enhancement in bi

9 IFN-alpha2a, systemic corticosteroids, or no treatment for 4 months.

10 Empagliflozin treatment for 48 h reduced the TmG in both individuals w

11 d to HPP for 5min (450MPa) and to ultrasonic treatment for 5min (600 and 1200W/L) followed by HPP for

12 Furthermore, leptin treatment for 9 days or more was sufficient to restore A

13 se 4 (PDE4) has been proposed as a potential treatment for a series of neuropsychological conditions

14 ma affects up to 1 in 6 patients who undergo treatment for a solid tumor in the United States.

15 ve gained momentum as the next generation of treatments for a variety of serious diseases.

16 were used to assess the utility of DEC salt treatment for achieving LF elimination, in comparison wi

17 n and contacted participants to determine if treatment for acute exacerbation was required.

18 a randomized clinical trial of endovascular treatment for acute ischemic stroke in the Netherlands.

19 t, no pharmacological prevention or specific treatment for acute pancreatitis exists.

20 road-spectrum and narrow-spectrum antibiotic treatment for acute respiratory tract infections in chil

21 ed that clinicians should reserve antibiotic treatment for acute rhinosinusitis in patients with pers

22 found that surgery could be a cost-effective treatment for adolescents with severe obesity if assesse

23 al therapeutic targets that may be useful as treatments for ADPKD.

24 There are no disease-modifying treatments for adult human neurodegenerative diseases.

25 bolization can serve as a safe and effective treatment for advanced-stage HCC patients with tumor PVT

26 nd could contribute to the identification of treatments for age-related cognitive deficits.SIGNIFICAN

27 l syndrome, clinical outcomes, pharmacologic treatment for alcohol withdrawal syndrome, and Clinical

28 pply might be improved to ensure appropriate treatment for all children with malaria.

29 Achieving one-stop diagnosis and treatment for all people with TB will require simpler, m

30 Allergen immunotherapy, the aetiological treatment for allergic respiratory diseases, has demonst

31 Treatments for alopecia areata (AA) have evolved over th

32 The current frontline symptomatic treatment for Alzheimer's disease (AD) is whole-body upr

33 ) represents the most effective single agent treatment for AML.

34 With no effective treatment for AMPH addiction to date, there is urgent ne

35 r-kidney transplant recipients who completed treatment for an episode of CMV infection/disease were i

36 tor drugs is likely to be the most effective treatment for an individual patient.

37 show that women who are currently receiving treatment for ANSD show an over-estimation of body size

38 terion standard evidence-based psychological treatments for anxiety disorders with less attrition.

39 fear is essential for formulating successful treatments for anxiety disorders.

40 and no apparent differences were found among treatments for any of these counts at any time point.

41 paper elucidates the development of specific treatments for aortic aneurysms over time and more broad

42 lds of medicine and applying them toward the treatment for asthma and allergy.

43 ements as a complementary or steroid-sparing treatment for asthma.

44 Overall, 48 990 children received treatment for asthma.

45 As treatments for asthma currently in development focus on

46 o had myelofibrosis and previous ruxolitinib treatment for at least 28 days who either required red b

47 potentially life-threatening consequence of treatment for autoimmune disease (AID) and an emerging c

48 Antifungal treatment is more complex than treatment for bacterial or most viral infections, and dr

49 Advances in treatments for biliary atresia and necrotising enterocol

50 ent of prostate cancer; however, AR-targeted treatment for breast cancer is an area of active investi

51 hamide and doxorubicin (Cyclo/Dox), a common treatment for breast cancer, to female BALB/c mice near

52 erse sample of patients who underwent recent treatment for breast cancer.

53 Androgen receptor-targeted treatments for breast cancer are in development and have

54 Traditional treatments for breast cancer fail to address therapy-res

55 ycosylation inhibitors as future combination treatments for breast cancer.

56 Low-molecular-weight heparin is the standard treatment for cancer-associated venous thromboembolism.

57 ide effect experienced by patients receiving treatment for cancer.

58 T-cell-based immunotherapies are promising treatments for cancer patients.

59 ey step in the development of more effective treatments for cancer.

60 The only treatment for celiac disease (CeD) is a lifelong gluten-

61 nderstand the effectiveness of screening and treatment for celiac disease, accuracy of screening test

62 Artesunate remains the mainstay of treatment for cerebral malaria, but it is less effective

63 cceptable safety in patients with >/=1 prior treatments for cGVHD.

64 ansplantation has been advocated as surgical treatment for children with HB involving 3 or 4 sectors

65 ss during the 2003-15 malaria programme, ACT treatment for children with malaria remains unacceptably

66 to elucidate the optimal indication and drug treatment for children.

67 is currently the first-line pharmacological treatment for children.

68 Treatment for chronic constipation in older people is ch

69 The efficacy of antiviral treatment for chronic hepatitis C virus (HCV) infection

70 Despite effective treatment for chronic hepatitis C, deficiencies in diagn

71 had a diagnosis of IBS, 19.9% were receiving treatment for chronic inflammatory bowel disease, 12.1%

72 adiofrequency denervation is a commonly used treatment for chronic low back pain, but high-quality ev

73 Fremanezumab as a preventive treatment for chronic migraine resulted in a lower frequ

74 virologic response (SVR) to interferon-based treatments for chronic hepatitis C virus infection, wher

75 sting that SCIg can be used as a maintenance treatment for CIDP.

76 B deserves further evaluation as a potential treatment for cirrhotic PH.

77 An effective, safe, and oral treatment for CL is required.

78 not support use of the studied pharmacologic treatments for cognitive protection in persons with norm

79 ildren aged 10 and under undergoing surgical treatment for COME from 35 hospitals in the UK, and thei

80 professionals and patients about antibiotic treatment for common infections.

81 Although there are effective treatments for common mental disorders associated with G

82 apeutic potential of inhibiting GnT-III as a treatment for controlling EOC growth and recurrence.

83 nalyses of clinical trials of corticosteroid treatment for COPD have shown that the blood eosinophil

84 previous COPD hospital contact, nor medical treatment for COPD, was registered.

85 To date, there are no AR variant-specific treatments for CRPC.

86 e to achieve more effective and personalized treatments for CTCL.

87 re represent potential new disease-modifying treatments for dementia.

88 ing donor pancreas transplant is a potential treatment for diabetic patients with end-organ complicat

89 ts than observation but a lower frequency of treatment for disease progression, mostly for asymptomat

90 of diseases and determine the most effective treatments for diseases.

91 ion becoming an increasingly routine form of treatment for diverse populations, and with internationa

92 icant advancement in developing an effective treatment for DMD.

93 2 years, eyes with NPDR receiving anti-VEGF treatment for DME may experience improvement in DR sever

94 electrodes implanted in patients undergoing treatment for drug-resistant epilepsy.

95 In India and South Africa, improvements in treatment for drug-sensitive and multidrug-resistant tub

96 als who received the minimally effective HCV treatment for dual, triple, or all-oral therapy had a 30

97 d treatment represents a standard palliative treatment for Duchenne muscular dystrophy (DMD) patients

98 tic avenues, there is currently no effective treatment for Duchenne muscular dystrophy (DMD), a letha

99 id use at HT (OR, 1.5; 95% CI, 1.0-2.2), and treatment for early rejection (OR, 2.0; 95% CI, 1.5-2.7)

100 there are currently no approved vaccines or treatments for EBOV, a better understanding of the biolo

101 sferase (COMT) inhibitors are an established treatment for end-of-dose motor fluctuations associated

102 Treatment for end-stage kidney disease is a major econom

103 viewed supports DMEK as a safe and effective treatment for endothelial failure.

104 The Systemic Treatment for Eye Diseases (SITE) Cohort Study suggested

105 modelling study used cross-sectional data on treatment for fever and RDT status for children younger

106 YAG vitreolysis is an untested treatment for floaters.

107 s aged 18 to 75 years with previous surgical treatment for fractures below the knee who were undergoi

108 The best treatment for fractures of the distal tibia remains cont

109 able, disease-modifying, and neuroprotective treatment for Friedreich's ataxia.

110 sease to mimic cases in which patients begin treatment for fulminant disease.

111 illance, advances in development of non-drug treatments for gastro-oesophageal reflux disease, safety

112 1 repletion may thus constitute an effective treatment for Glut1 DS.

113 Cefixime was recommended as a single-dose treatment for gonorrhoea from 2005 to 2010, during which

114 The choice of primary treatment for group D retinoblastoma should be carefully

115 d therapeutic (eg, neuroprotective drugs and treatments for haemorrhagic stroke) options in the preho

116 whether low-dose naltrexone is an effective treatment for Hailey-Hailey disease.

117 disease and either had received no previous treatment for HCV infection or had received previous tre

118 of cirrhosis, who had not received previous treatment for HCV infection.

119 The timing of initiation of antiviral treatment for HCV patients with HCC or DCC relative to L

120 Effective treatments for HCV genotype 3 infection are limited (2 D

121 a better personalization of chemo-radiation treatments for head-and-neck cancer patients from differ

122 Because there are currently no biological treatments for hearing loss, we sought to advance gene t

123 resynchronization therapy (CRT) is a potent treatment for heart failure in the setting of ventricula

124 towards a new generation of stem cell-based treatment for heart failure.

125 ulmonary bypass would benefit from potential treatments for hemolysis and plasma hemoglobin-associate

126 iver diseases and could represent a curative treatment for hemophilia A.

127 Despite the availability of curative treatment for hepatitis C virus (HCV) infection, because

128 This information could be used to design new treatments for herpesvirus infections.

129 Phlebotomy constitutes the established treatment for HFE-related hemochromatosis.

130 re multifactorial and there are no effective treatments for HFpEF, partially attributable to the lack

131 sed studies will continue to aim to optimise treatment for high-risk neuroblastoma.

132 o helpful to inform appropriate conservation treatments for his works.

133 bitors (NRTIs) are recommended as first-line treatment for HIV, and coformulated fixed-dose combinati

134 ne and emtricitabine, as initial and ongoing treatment for HIV-1 infection.

135 nd TGF-beta could be developed into a viable treatment for human HBV infection.

136 gress made in developing a vaccine and novel treatments for human immunodeficiency virus (HIV).

137 57 cognitively intact older adults receiving treatment for hypertension were studied from 1997 to 200

138 The treatment for hyponatremia is chosen on the basis of dur

139 Treatments for hyposalivation are limited to the use of

140 F-budesonide could become the first specific treatment for IgA nephropathy targeting intestinal mucos

141 y several specialists to develop alternative treatments for IgG4-related disease.

142 tment alternative to conventional root canal treatment for immature teeth.

143 ision problems and the effectiveness of some treatments for improving visual acuity outcomes.

144 of new immunotherapy agents and customizing treatment for individual patients.

145 d access to lifesaving outpatient antibiotic treatment for infants with severe infection during the n

146 methyl pentanedioic acid (2-PMPA) as a novel treatment for inflammatory bowel disease (IBD).

147 There are no approved treatments for Lassa fever, which is endemic to the same

148 to dissect the efficiency and safety of new treatments for late ABMR.

149 y be particularly valuable for investigating treatments for less common cancers, which frequently lac

150 ith their patients when selecting first-line treatment for locally advanced or metastatic soft-tissue

151 For many years, first-line treatment for locally advanced or metastatic soft-tissue

152 herapy could represent an effective targeted treatment for long-term disease control in severely affe

153 port the value of early initiation of statin treatment for low-density lipoprotein cholesterol reduct

154 todynamic therapy, a novel tissue-preserving treatment for low-risk prostate cancer, has shown favour

155 ed photodynamic therapy is a safe, effective treatment for low-risk, localised prostate cancer.

156 ninvasive pharmacologic and nonpharmacologic treatments for low back pain.

157 ractical approach to larger-scale ivermectin treatment for lymphatic filariasis and onchocerciasis in

158 cability to CRVO and HRVO patients receiving treatment for macular edema.

159 ould be considered a safe and well tolerated treatment for malignant dysphagia in the palliative sett

160 sychostimulant addiction, the only effective treatment for many addicts is contingency management, a

161 matopoietic stem cell transplantation, a key treatment for many disorders, is intertwined with T cell

162 eous minimally invasive therapy a first-line treatment for many patients at extreme risk for conventi

163 Nevertheless, optimal treatment for many phenotypes of PE remains uncertain.

164 medicine for optimizing and individualizing treatments for many cancer entities.

165 Effective drug treatments for many psychiatric diseases are lacking, an

166 nal Neovascularization NOS." Type of initial treatment for mCNV was categorized as the administration

167 F injection was the most frequently utilized treatment for mCNV.

168 fectiveness and safety of 3 common alternate treatments for MDD.

169 of 280 participants (69%) had never received treatment for MDR tuberculosis.

170 We found a reduced risk of TB incidence with treatment for MDR-LTBI, suggesting effectiveness in prev

171 a functional analog, could be developed as a treatment for metabolic disorders.

172 ere stratified by metastasis stage, previous treatment for metastatic melanoma, and Eastern Cooperati

173 r serous retinal detachment during nivolumab treatment for metastatic melanoma.

174 (anti-programmed death-ligand 1 [PD-L1]) as treatment for metastatic urothelial cancer in cisplatin-

175 vide an important approach to the beneficial treatment for METH addiction.

176 BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia".

177 easing the available repertoire of effective treatments for mood and anxiety disorders represents a c

178 ediatric Acute Lymphoblastic Leukaemia (ALL) treatment for more than 40 years.

179 for an interaction between subphenotype and treatment for mortality.

180 ective and neuroreparative disease-modifying treatment for MS.

181 therapeutic targeting of the microbiota as a treatment for MS.

182 nique was adapted to develop a simple sample treatment for multi-residue pesticide analysis in milk s

183 Oxytocin (OT) is a potential treatment for multiple neuropsychiatric disorders.

184 tion by pharmacological means as a potential treatment for MYC-dependent tumors.

185 gh urban-rural disparities in evidence-based treatment for myocardial infarction in China have largel

186 observational study that commenced anti-VEGF treatment for nAMD between January 2006 and January 2017

187 ic surgery may be an effective but expensive treatment for NASH.

188 m studies and RCTs assessing the efficacy of treatments for NCP.

189 Stem cell treatments for neurodegenerative diseases are expected t

190 -inhibitor should be explored as a potential treatment for neutrophil-induced inflammation.

191 At its inception, there were no effective treatments for NF1 and few promising approaches on the h

192 ctor cells may provide benefit over existing treatments for NHL.

193 Dacryocystorhinostomy, the definitive treatment for NLDO, has a high success rate (80%-100%) w

194 n the verge of becoming a powerful analgesic treatment for numerous conditions, including osteoarthri

195 We review the use of MBS as a treatment for obesity and obesity-related conditions and

196 view the benefits and harms of screening and treatment for obesity and overweight in children and ado

197 Buprenorphine is an efficacious, widely used treatment for opioid use disorder (OUD).

198 are the most widely prescribed pharmacologic treatment for osteoporosis and reduce fracture risk in p

199 In an effort to find new and safer treatments for osteoporosis and frailty, we describe a n

200 n developing suitable post-synthesis thermal treatments for other alloy nanocatalysts as well.

201 diotherapy as part of the standard course of treatment for ovarian, prostate, colon, and bladder canc

202 tients who needed intravenous acetylcysteine treatment for paracetamol overdose had circulating bioma

203 the effectiveness of minimal interventional treatments for participants with chronic low back pain (

204 ever, there is an unmet need for intravenous treatment for patients admitted to hospital with severe

205 Treatment for patients who cannot receive penicillin and

206 tors may be a potentially useful therapeutic treatment for patients whose tumours contain a high frac

207 rituximab consolidation might be sufficient treatment for patients with a complete response after ri

208 Cardiac pacing is an effective treatment for patients with bradycardia due to sinus nod

209 The considerable between-center variation in treatment for patients with brain injury can only partly

210 Renal transplantation is the preferred treatment for patients with end-stage renal disease.

211 ACE is a feasible, safe, and well-tolerated treatment for patients with HCC; it is highly effective

212 In this Seminar, we discuss existing treatment for patients with lung cancer and the promise

213 ally modified T cells is being explored as a treatment for patients with metastatic cancer.

214 icacy and safety of clemastine fumarate as a treatment for patients with multiple sclerosis.

215 nalidomide plus dexamethasone is a reference treatment for patients with newly diagnosed myeloma.

216 These findings do not support this treatment for patients with symptomatic knee osteoarthri

217 proactive and targeted approach to step-down treatment for patients with well-controlled asthma.

218 de therapy (PRRT) has become a well-accepted treatment for patients with well-differentiated inoperab

219 ib with other systemic agents and third-line treatments for patients who fail or who do not tolerate

220 th particular promise for development of new treatments for patients with fibrotic kidney disease.

221 rstand the benefits and burden of palliative treatments for patients with recurrent head and neck can

222 nalized medicine, including cancer-targeting treatments for patients.

223 ation of engrafted NSC/NPCs as a restorative treatment for PD.

224 To determine the effectiveness of NSAID treatment for PDA in reducing mortality and moderate/sev

225 t frequency to determine the effect of NSAID treatment for PDA on mortality and BPD.

226 otentially lead to the development of better treatments for people with ALS.

227 Emerging innovative treatments for perianal Crohn disease are now available

228 hibition of CTGF by FG-3019 might be a novel treatment for PF through the regulation of fibroblast an

229 combination therapies are the first line of treatment for Plasmodium falciparum infections worldwide

230 reatments and could be considered for rescue treatment for Plasmodium falciparum malaria.

231 maging and liver lymphatic embolization as a treatment for PLE.

232 tion and reprocessing (EMDR) is an effective treatment for posttraumatic stress disorder.

233 t in guiding the decision to initiate statin treatment for primary prevention in older adults require

234 a potential clinical tool to personalize ADT treatment for prostate cancer by predicting which men ma

235 roach to examine the association of ADT as a treatment for prostate cancer with the subsequent develo

236 arding the comparative harms of contemporary treatments for prostate cancer.

237 underwent iodine-125 (I-125) EPBT as primary treatment for PUM between 1985 and 2015.

238 who discontinued the study before the end of treatment for reasons determined to be unrelated to HCV

239 interaction may serve as a potential salvage treatment for recurrent NPC.

240 ets, have been used as a non-pharmacological treatment for refractory epilepsy.

241 Epilepsy surgery is an effective treatment for refractory focal epilepsy.

242 fied T (CAR-T)-cell immunotherapy is a novel treatment for refractory or relapsed B-cell malignancies

243 renal vasodilation using serelaxin as a new treatment for renal dysfunction in cirrhosis, although f

244 Current treatments for rheumatoid arthritis (RA) do not reverse

245 Valproic acid (VPA) is a proposed treatment for RP and other neurodegenerative disorders,

246 The development of treatments for SCLC has remained stagnant for decades, a

247 ic stem cells have led to safe and effective treatments for several PIDs, including forms of severe c

248 d- and threat-related dysfunction to improve treatment for severe irritability in youths.

249 pioid receptors is an attractive alternative treatment for severe pain.

250 mens has the potential to increase access to treatment for sick young infants who cannot be referred

251 activated persulfate may be a useful in situ treatment for sites contaminated with polyfluoroalkyl su

252 ithout requiring a post-deposition annealing treatment for solvent removal.

253 tome-based drug discovery has identified new treatments for some complex diseases, but has not been a

254 Additionally, treatments for specific complications have emerged and a

255 effect of delayed 9 cis retinoic acid (9cRA) treatment for stroke.

256 United States, millions of individuals need treatment for substance use disorders but few receive it

257 iomyopathy and may underlie potential target treatments for such conditions.

258 with depression (PHQ-9 score >9) who sought treatment for symptoms of depression between the baselin

259 ment, we set out to identify novel effective treatments for T-PLL patients.

260 lantation is considered one of the potential treatments for T1DM but limited islet survival and their

261 icin was superior to itraconazole as initial treatment for talaromycosis with respect to 6-month mort

262 The median duration of treatment for the 204 patients was 5.7 months (IQR 2.8-1

263 tation of a radioactive iodine 125 plaque as treatment for the tumor.

264 ional risk for disease and the design of new treatments for the behavioral deficits associated with n

265 Development of treatments for the neurological manifestations of MPS ha

266 verage: higher coverage requires fewer total treatments for the same health gain.

267 tation of Ahmed valve proved to be effective treatment for these patients (IOP < 21 mmHg).

268 prefrontal cortex (dlPFC), but there are few treatments for these debilitating symptoms.

269 ide opportunities for the development of new treatments for these diseases.

270 ansplantation have a grim prognosis, and new treatments for these patients are clearly needed.

271 primary care settings would expand access to treatment for this condition.

272 light the need to develop effective systemic treatments for this disease.

273 d in the development of a vaccine and/or new treatments for this disease.

274 ight the importance of studying sex-specific treatments for this disorder.

275 ion antidepressants (SGAs) versus most other treatments for this disorder.

276 ique advantages in the drive to discover new treatments for this prevalent and oppressive condition.

277 ion of ALK and MDM2 may provide an effective treatment for TP53 wild-type neuroblastoma with ALK aber

278 We examined variation in treatment for traumatic brain injury by assessing factor

279 y, efficacy and side effect rate of lesional treatments for tremor are presented separately alongside

280 New treatments for triple-negative breast cancer (TNBC) are

281 tially higher in children with HIV receiving treatment for tuberculosis (especially without antiretro

282 in) has been used as a first line antibiotic treatment for tuberculosis (TB), and it remains the corn

283 s and developed individualized combinatorial treatments for two subtypes with distinct pathway activa

284 slet transplantation is a promising clinical treatment for type 1 diabetes, but success is limited by

285 ablative therapy for threshold ROP, earlier treatment for type 1 or pre-threshold disease has been f

286 The potential role of anti-VEGF treatment for type 1 ROP has become a focus in recent ye

287 g GPR40 agonists is described as a potential treatment for type 2 diabetes.

288 -1R) agonists are increasingly being used as treatment for type 2 diabetes.

289 ransplantation remains the gold standard for treatment for type I diabetes providing an insulin-indep

290 lowing the Edmonton Protocol, is a promising treatment for type I diabetics.

291 on treatment (ACT) is the recommended rescue treatment for uncomplicated malaria.

292 Responders were withdrawn from treatment (for up to 36 weeks) and re-treated with adali

293 Delaying VLX103 treatment for up to 3 hours after GalN/LPS administratio

294 A patient subgroup remained on blinded treatment for up to 52 weeks.

295 Specialist treatments for urgency incontinence include onabotulinum

296 ho were scheduled for enucleation as primary treatment for uveal melanoma.

297 -stereochemistry have long been an effective treatment for viral infections because of the strong D-s

298 These findings suggest an effective treatment for vomiting in positive FPIES OFCs and allow

299 Future treatments for XLH should target both systemic and local

300 lopment and/or more judicious application of treatments for youth.